Services of MTRC

MTRC is joining ISPOR Europe 2026 in Vienna on 8–11 November — a great venue to discuss the evolving evidence requirements and reimbursement challenges shaping market access for medical technologies in Europe. Visit us at booth #416 to meet our team, or book a meeting in advance with MTRC Director Oleg Borisenko to discuss your specific European market access and evidence strategy needs.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of September 14th, we plan to work on 15 projects. Review the complete list of planned activities in this post.

The new MTRC White Paper provides a practical overview of the evidence, methodology, and dossier submission requirements for medical devices and IVDs under the EU Joint Clinical Assessment framework.

European countries differ substantially in the predictability, speed, evidence burden, and complexity of obtaining reimbursement and enabling routine hospital use of medical devices. This online seminar will present the methodology and key findings of the MTRC Reimbursement, Policy & HTA Attractiveness Index 2026, which compares 12 European markets across six dimensions and identifies Germany, Denmark, and Switzerland as the leading markets. It will explain how manufacturers can use the findings to support country prioritization, launch sequencing, evidence planning, and realistic time-to-revenue expectations, while recognizing that the results must be adapted to the characteristics of each technology. The seminar will be delivered by Oleg Borisenko, MD, PhD, on 27 August 2026 at 17:00 CET, is open only to medical technology industry representatives, and will not be recorded.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of August 24th, we plan to work on 11 projects. Review the complete list of planned activities in this post.

The European MedTech market access environment continued to evolve in 2026, with important developments in reimbursement, healthcare policy, HTA methodology, national access pathways, and innovative payment mechanisms. This online seminar will review the most significant developments of the year, including progress in implementing EU Joint Clinical Assessments for selected medical devices and IVDs. It will explain how these changes may affect evidence generation, reimbursement strategy, country prioritization, launch sequencing, and time to access, while highlighting practical actions manufacturers should consider for 2027 and beyond. The seminar will be delivered by Dr Oleg Borisenko on 17 December 2026 at 17:00 CET, is open only to representatives of the medical technology industry, and will not be recorded.

Regulatory approval does not automatically provide the clinical and health economic evidence needed to secure reimbursement, obtain a positive HTA recommendation, or support routine adoption of a medical device across Europe. This online seminar will explain how evidence expectations vary by country and pathway. It will review typical expectations about comparator, patient population, study designs, duration of follow-up and outcomes. It will also examine when health economic evidence may be required, and how manufacturers can identify evidence gaps and align development programs with future reimbursement and HTA needs. The seminar will be delivered by Dr Oleg Borisenko on 29 October 2026 at 17:00 CET, is open only to representatives of the medical technology industry, and will not be recorded.

The EU Joint Clinical Assessment (JCA) introduces a mandatory, centralized evaluation of the relative clinical effectiveness and safety of selected high-risk medical devices and in-vitro diagnostic devices, while national authorities retain responsibility for pricing, reimbursement, cost-effectiveness, and funding decisions. This online seminar will explain which technologies may be selected for JCA, the main methodological requirements, and the specific role of the PICO framework in defining evidence expectations. It will also outline practical steps manufacturers should take to align clinical development and evidence-generation strategies with the emerging JCA requirements. The seminar will be delivered by MTRC Director, Oleg Borisenko, on 24 September 2026 at 17:00 CET, is open only to medical technology industry representatives, and will not be recorded.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of August 10th, we plan to work on 14 projects. Review the complete list of planned activities in this post.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of July 27th, we plan to work on 13 projects. Review the complete list of planned activities in this post.

MTRC is introducing a Market Access Director-for-Hire model in collaboration with Markus Siebert, Partner of MTRC and Head of Metis Market Access Consulting. The model gives MedTech companies flexible access to senior market access leadership to support European launches, internal decision-making, and strategy implementation.

MTRC has opened registration for its free European Market Access Training Program for MedTech professionals, starting on 15 October 2026.